Company: SHPH
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001641172-25-023263
Chunk: 16

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part II, Item 4
Chunk 16
---
Not
Applicable.

ITEM
5. OTHER INFORMATION

During
the quarter ended June 30, 2025, none of our directors or executive officers adopted or terminated any “Rule 10b5-1 trading arrangement”
or “non-Rule 10b5-1 trading arrangement” (as each item is defined Item 408(a) of Regulation S-K).

Item
6. Exhibits

The
following exhibits are filed or furnished with this report:

    Exhibit
    No.
     
    Description
    of Exhibit
  
    10.1
     
    Securities Purchase Agreement dated June 20, 2025 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on June 25, 2025)
  
    10.2
     
    Registration Rights Agreement dated June 20, 2025 (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed on June 25, 2025)
  
    10.3
     
    Form of Pre-Funded Warrant (incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K filed on June 25, 2025)
  
    31.1
     
    Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*
  
    31.2
     
    Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*
  
    32.1
     
    Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**
  
    32.2
     
    Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**
  
    101.INS
     
    Inline
    XBRL Document Set for the financial statements and accompanying notes in Part I, Item 1, of this Quarterly Report on Form 10-Q.
  
    104
     
    Cover
    Page Interactive Data File (embedded within the Inline XBRL document)

*
Filed herewith.

**Furnished
her